Stock listing

NASDAQ:MTVA MetaVia Inc. Stock

Home listing (NASDAQ) of MetaVia Inc.

Follow MetaVia Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:MTVA

$1.01 USD -0.05 (-4.7%)

Close on Nov 20, 2026

Past year -86.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.999 – $1.10 USDNov 20, 2026
Volume
38,724 sharesNov 20, 2026
Market cap
$6.81M USDAt the close on Nov 20, 2026 · price × 6.74M shares outstanding
52-week range
$0.966 – $13.42 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$160,402 USDMedian day 58,853 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
MetaVia Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:MTVA · Home$1.01 USD-0.05 (-4.7%)38,724$1.059$1.10$0.999$1.06Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:MTVA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.01-0.05-4.7%$1.059$1.10$0.99938,724
$1.06-0.19-15.2%$1.22$1.24$1.0691,476
$1.25+0.045+3.7%$1.23$1.38$1.18693,884
$1.205-0.095-7.3%$1.28$1.30$1.18558,853
$1.300.000.0%$1.431$1.431$1.25149,172
$1.30-0.14-9.7%$1.45$1.45$1.29555,064
$1.44-0.05-3.4%$1.48$1.609$1.402128,885
$1.49-0.12-7.5%$1.60$1.66$1.49105,041
$1.61+0.18+12.6%$1.40$1.776$1.33462,543
$1.43+0.34+31.2%$1.10$1.44$1.09942,700
$1.09-0.25-18.7%$1.40$1.423$1.0161,078,700
$1.34+0.08+6.3%$1.26$1.45$1.26147,600
$1.26+0.09+7.7%$1.17$1.26$1.1773,200
$1.17+0.05+4.5%$1.19$1.219$1.1554,100
$1.12-0.07-5.9%$1.20$1.29$1.1272,500
$1.19+0.05+4.4%$1.15$1.25$1.1266,500
$1.14-0.01-0.9%$1.17$1.19$1.1193,200
$1.15-0.065-5.3%$1.27$1.27$1.1568,400
$1.215-0.165-12.0%$1.41$1.41$1.215136,100
$1.38-0.01-0.7%$1.39$1.50$1.3699,600
$1.39+0.05+3.7%$1.35$1.395$1.3533,100
$1.34+0.05+3.9%$1.29$1.37$1.2942,200
$1.29+0.06+4.9%$1.26$1.32$1.2021,000
$1.23-0.03-2.4%$1.29$1.32$1.22554,300
$1.26-0.11-8.0%$1.38$1.43$1.2675,700
$1.37+0.01+0.7%$1.35$1.44$1.32550,100
$1.36-0.07-4.9%$1.40$1.435$1.3540,500
$1.43-0.02-1.4%$1.52$1.52$1.41565,400
$1.45+0.04+2.8%$1.43$1.589$1.41137,000
$1.41+0.07+5.2%$1.35$1.44$1.3549,600
$1.34-0.12-8.2%$1.47$1.48$1.33112,000
$1.46-0.02-1.4%$1.47$1.52$1.4630,800
$1.48-0.06-3.9%$1.52$1.54$1.4586,100
$1.540.000.0%$1.55$1.587$1.5453,100
$1.540.000.0%$1.56$1.65$1.5161,400
$1.54-0.03-1.9%$1.59$1.605$1.5246,600
$1.57-0.09-5.4%$1.64$1.66$1.5565,100
$1.66-0.01-0.6%$1.64$1.67$1.6126,100
$1.67+0.01+0.6%$1.65$1.70$1.62135,000
$1.66+0.03+1.8%$1.68$1.68$1.6128,700
$1.630.000.0%$1.662$1.662$1.6163,600
$1.63-0.05-3.0%$1.65$1.665$1.6137,600
$1.68+0.01+0.6%$1.69$1.69$1.6431,300
$1.67-0.06-3.5%$1.65$1.701$1.6445,300
$1.73+0.14+8.8%$1.55$1.73$1.55103,800
$1.59+0.05+3.2%$1.551$1.59$1.5238,900
$1.54-0.04-2.5%$1.57$1.59$1.5245,700
$1.58-0.04-2.5%$1.67$1.67$1.5652,600
$1.62-0.04-2.4%$1.64$1.87$1.6076,600
$1.66-0.09-5.1%$1.75$1.795$1.6557,000
$1.75+0.01+0.6%$1.75$1.83$1.74104,900
$1.74+0.04+2.4%$1.70$1.85$1.52609,300
$1.70-0.05-2.9%$1.76$1.81$1.7042,800
$1.75-0.09-4.9%$1.82$1.85$1.7081,100
$1.84+0.02+1.1%$1.803$1.93$1.7882,900
$1.82+0.10+5.8%$1.70$1.84$1.69979,600
$1.720.000.0%$1.69$1.73$1.6551,400
$1.72+0.02+1.2%$1.70$1.74$1.6823,300
$1.70+0.04+2.4%$1.69$1.732$1.6737,700
$1.66-0.02-1.2%$1.69$1.73$1.6539,700
$1.68+0.04+2.4%$1.56$1.69$1.5648,600
$1.64+0.11+7.2%$1.53$1.80$1.53246,600
$1.53+0.07+4.8%$1.44$1.53$1.4437,900
$1.46+0.02+1.4%$1.45$1.495$1.4542,100
$1.44-0.03-2.0%$1.47$1.47$1.4342,200

Splits

4 splits since 2019 · NASDAQ:MTVA · every price before a split is adjusted for it

DayRatioWhat
1-for-11Consolidation
1-for-8Consolidation
1-for-30Consolidation
1-for-25Consolidation
Ticker
NASDAQ:MTVA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All MetaVia Inc. news

MetaVia Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
34 in the last 12 months · 116 in all · newest Nov 17, 2026 · oldest 2021
Decks
26 decks · latest Nov 13, 2026

Where MetaVia Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:MTVA · Home listing · This pageNASDAQUnited StatesUSD
BOATS:MTVABOATSUnited StatesUSD

Valuation

Price/book 2.8× against a median of 2.7×: 6th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$1.97M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
2.8×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.22

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
MetaVia Inc. · NASDAQ:MTVAUS$6.81M−US$1.97Mn/an/an/a2.8×n/a0.0×1.22
AEON Biopharma, Inc. · AMEX:AEONUS$7.27M−US$4.15Mn/an/an/a3.0×n/a0.0×1.04
Pila Pharma AB · OMXSTO:PILAUS$7.01MUS$6.70Mn/an/an/a4.5×n/a0.0×n/a
Cadrenal Therapeutics, Inc. · NASDAQ:CVKDUS$7.01MUS$3.95Mn/an/an/a2.4×n/a0.0×1.60
Ensysce Biosciences, Inc. · NASDAQ:ENSCUS$7.00M−US$22.51Mn/a−3.6×n/a0.3×n/a0.0×1.28
Arctic Bioscience AS · OSL:ABSUS$7.00MUS$11.38Mn/a2.8×n/a0.4×−102.3%0.3×n/a
Alaunos Therapeutics, Inc. · NASDAQ:TCRTUS$6.99MUS$6.37Mn/a2,124×n/a7.2×n/a0.0×0.90
Curanex Pharmaceuticals Inc · NASDAQ:CURXUS$6.92MUS$5.88Mn/an/an/a2.7×n/a0.2×0.84
Cambium Bio Ltd · ASX:CMBUS$6.82MUS$6.18Mn/a14.6×n/a4.3×−638.4%0.1×n/a
Aligos Therapeutics, Inc. · NASDAQ:ALGSUS$6.64M−US$12.55Mn/a−2.1×n/a0.6×n/a1.1×1.63
ZEO ScientifiX Inc. · OTC:ZEOXUS$6.51MUS$5.27Mn/a1.0×n/an/a−106.2%n/a0.54
Median of the othersUS$6.99MUS$5.57M1.9×2.7×−106.2%0.0×1.04

Forecasts

1 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
19.33 USD · Analysts' mean
EPS, year to Dec 2026
-2.52 · 3 analysts

Team and board

Officers

OfficerRole
Hyung Heon KimChief Executive Officer and President
Marshall H. WoodworthChief Financial Officer
Sarah BrowneChief Medical Officer

Board

DirectorRole
Andrew KovenChairman of the Board
D. Gordon StricklandIndependent Director
Hyung Heon KimChief Executive Officer and President
James P. TursiIndependent Director
Jason GrovesIndependent Director
Mark A. GlickmanIndependent Director
Michael SalsburyIndependent Director

Events

QuarterResultsShare move
Q3 2026Nov 13, 2026 · Before open0.0%
Q2 2026Aug 6, 2026 · After close+2.8%
Q1 2026May 14, 2026 · After close−6.7%
Q3 2025Nov 6, 2025 · Before open−15.0%
Q2 2025Aug 7, 2025 · Before open+2.9%
Q1 2025May 14, 2025+4.0%
Q4 2024Mar 20, 2025 · Before open−2.5%
Q3 2024Nov 7, 2024 · Before open−2.2%
Q2 2024Aug 14, 2024 · Before open+3.2%
Q1 2024May 9, 2024+0.8%
All 20 quarters
QuarterResultsShare move
Q4 2023Mar 28, 2024 · After close−0.7%
Q3 2023Nov 13, 2023 · After close−1.8%
Q2 2023Aug 9, 2023 · After close+13.2%
Q1 2023May 12, 2023 · After close+3.1%
Q4 2022Mar 30, 2023−2.7%
Q3 2022Nov 14, 2022 · After close+10.1%
Q2 2022Aug 16, 2022−2.0%
Q1 2022May 25, 2022−15.2%
Q3 2021Nov 15, 2021 · Before open+1.1%
Quarter to Jun 30, 2021Aug 16, 2021 · Before open+1.1%

Open Events

Decks

DeckKindSlidesDate
Corporate Update (November 2026)Corporate update42 slidesNov 13, 2026
Investor Presentation (November 2026)Investor deck54 slidesNov 5, 2026
Investor Presentation (August 2026)Investor deck37 slidesAugust 2026
Investor Presentation (May 2026)Investor deck37 slidesMay 14, 2026
Investor Presentation (March 2026)Investor deck37 slidesMar 26, 2026
IPO Roadshow (January 2026)IPO roadshow52 slidesJan 6, 2026
Investor Presentation (November 2025)Investor deck30 slidesNov 6, 2025
Investor Presentation (August 2025)Investor deck30 slidesAug 7, 2025
Investor Presentation (May 2025)Investor deck30 slidesMay 21, 2025
Investor Presentation (April 2025)Investor deck29 slidesApr 22, 2025
All 26 decks
DeckKindSlidesDate
Investor Presentation (April 2025)Investor deck26 slidesApr 15, 2025
Corporate Update (January 2025)Corporate update16 slidesJan 10, 2025
Investor Presentation (November 2024)Investor deck29 slidesNov 29, 2024
NeuroBo Pharmaceuticals — Investor Presentation (October 2024)Investor deck29 slidesOct 7, 2024
NeuroBo Pharmaceuticals — Investor Presentation (July 2024)Investor deck31 slidesJul 16, 2024
NeuroBo Pharmaceuticals — Investor Presentation (April 2024)Investor deck27 slidesApr 16, 2024
NeuroBo Pharmaceuticals — Investor Presentation (February 2024)Investor deck26 slidesFeb 14, 2024
NeuroBo Pharmaceuticals — Investor Presentation (December 2023)Investor deck25 slidesDec 7, 2023
NeuroBo Pharmaceuticals — Investor Presentation (September 2023)Investor deck34 slidesSep 22, 2023
NeuroBo Pharmaceuticals — IPO Roadshow (October 2022)IPO roadshow30 slidesOct 24, 2022
EASD 57th Annual Meeting 2021Conference10 slidesOct 1, 2021
NeuroBo Pharmaceuticals — Investor Presentation (March 2021)Investor deck27 slidesMar 5, 2021
NeuroBo Pharmaceuticals — Investor Presentation (January 2021)Investor deck28 slidesJan 8, 2021
NeuroBo Pharmaceuticals — Investor Presentation (January 2020)Investor deck26 slidesJan 13, 2020
Gemphire Therapeutics — Merger or Acquisition (September 2019)Merger or acquisition23 slidesSep 24, 2019
Gemphire Therapeutics — Merger or Acquisition (July 2019)Merger or acquisition16 slidesJul 25, 2019

Open Decks

Financings

RaiseDate
Public offering of class A Units and Class B Units (common stock or equivalents with Series C and Series D Warrants)
Closed: US$9.3M raised · US$3.1 a unit · Warrants at US$3.1 for 60 months · Ladenburg Thalmann & Co. Inc.
Dealers: Ladenburg Thalmann & Co. Inc. (lead)
Use of proceeds: Working capital and general corporate purposes, including continued clinical development of DA-1726 for obesity
Jan 16, 2026
Private placement of common stock and pre-funded warrants
Closed: US$10M raised · US$0.71 a share · Ladenburg Thalmann & Co. Inc.
Dealers: Ladenburg Thalmann & Co. Inc. (lead)
Use of proceeds: Working capital and corporate purposes, including continued clinical development of DA-1726 for obesity
May 14, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Gemphire Therapeutics Inc. Priced at US$10.00 a share on Aug 4, 2016.

Price
US$10.00 a share
Shares offered
3,000,000 shares of common stock
Offering size
US$30 million
Underwriters' option
Up to 450,000 more shares
Listing
GEMP on the Nasdaq Global Market
Underwriters
Jefferies, RBC Capital Markets, Canaccord Genuity, Laidlaw & Company (UK) Ltd., LifeSci Capital · In the order on the cover
Shares delivered
On or about Aug 10, 2016

Steps

StepWhen
Draft sent to the SEC in confidenceSep 11, 2015
Filed publiclyApr 18, 2016
Amended twiceNewest Aug 4, 2016
Shares registered with an exchangeJun 20, 2016
Declared effective by the SECAug 4, 2016
Final prospectus, with the priceAug 8, 2016

Open IPO · From the cover of the final prospectus (424B4) filed Aug 8, 2016

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue000000
Cost of revenue19.0K24.0K7.00K28.0K72.0K67.0K
Gross profit-19.0K-24.0K-7.00K-28.0K-72.0K-67.0K
Research and development6.80M21.6M9.16M2.78M6.55M4.53M5.32M5.07M22.7M8.74M
Selling, general and administrative6.91M7.26M6.73M8.64M8.75M7.85M2.70M1.60M10.4M5.96M
Operating income-13.7M-28.8M-15.9M-19.6M-15.3M-29.7M-20.2M-15.5M-33.1M-14.7M
Depreciation and amortization19.0K20.0K6.00K20.0K48.0K46.0K17.0K
EBITDA-13.7M-28.8M-15.9M-19.6M-15.3M-29.7M-20.2M
Interest expense02.19M022.0K40.0K286.0K
Income before tax-13.0M-27.6M-12.5M-14.0M-15.3M-29.7M-21.3M-15.5M-33.4M-14.6M
Income tax0000000000
Net income-13.0M-27.6M-12.5M-14.0M-15.3M-29.7M-21.3M-15.5M-33.4M-14.6M
Earnings per share, basic-7.35-39.13-2.46-43.42-19.81-1.83-4.08-3.65-3.23-2.57
Earnings per share, diluted-7.35-39.13-2.46-43.42-19.81-1.83-4.08-3.65-3.23-2.57

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents10.3M16.0M22.4M33.4M16.4M10.1M13.9M2.85M18.5M24.0M
Current assets10.9M16.1M22.5M33.5M16.6M10.7M14.1M3.81M19.0M24.7M
Property, plant and equipment17.0K34.0K46.0K2.00K110.0K155.0K200.0K3.00K
Total assets11.1M16.3M22.8M33.5M16.8M11.0M14.5M3.82M19.0M24.8M
Accounts payable1.06M3.88M821.0K708.0K830.0K2.58M638.0K170.0K4.03M2.01M
Current liabilities5.65M8.27M5.96M11.8M2.16M3.69M2.08M219.0K6.39M4.12M
Total debt210.0K136.0K203.0K71.0K94.0K116.0K9.58M10.0M
Total liabilities5.79M8.33M6.10M11.8M2.20M3.77M2.18M360.0K15.1M4.12M
Shareholders' equity5.33M7.93M16.7M21.8M14.6M7.20M12.3M-13.3M25.0K20.6M
Shares outstanding2.31M785.2K4.91M3.18M888.7K19.7M15.6M5.17M10.6M9.27M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-15.7M-24.7M-10.8M-11.7M-15.1M-10.8M-7.04M-14.5M-26.9M-11.0M
Capital spending-2.00K-8.00K-50.0K0-3.00K-4.00K-214.0K-3.00K00
Free cash flow-15.7M-24.7M-10.8M-11.7M-15.1M-10.8M-7.25M-14.5M-26.9M-11.0M
Cash from investing-2.00K-8.00K-50.0K8.00K-586.0K69.0K-6.06M-3.00K
Cash from financing9.96M18.3M-80.0K28.7M22.0M6.86M24.2M17.2M21.3M31.5M
Change in cash-5.74M-6.42M-10.9M17.0M6.31M-3.84M11.1M481.0K-5.56M20.4M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 18, 2026Current reportSEC
8-K · Current reportNov 17, 2026Current reportSEC
8-K · Current reportNov 16, 2026Current reportSEC
10-Q · Quarterly reportNov 13, 2026Quarterly reportSEC
8-K · Current reportNov 13, 2026ResultsSEC
8-K · Current reportNov 12, 2026Current reportSEC
8-K · Current reportNov 5, 2026Current reportSEC
8-K · Current reportOct 28, 2026Current reportSEC
4 · Change in ownershipOct 13, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 13, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportOct 13, 2026Current reportSEC
8-K · Current reportSep 9, 2026Current reportSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
8-K · Current reportJul 9, 2026Current reportSEC
8-K · Current reportJul 2, 2026Current reportSEC
424B5 · ProspectusJul 2, 2026Offer documentSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
S-8 · Registration statement for employee plansJun 8, 2026Offer documentSEC
8-K · Current reportJun 8, 2026Management or board changeSEC
8-K · Current reportJun 8, 2026Current reportSEC
8-K · Current reportMay 27, 2026Current reportSEC
8-K · Current reportMay 18, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 14, 2026ResultsSEC
8-K · Current reportMay 11, 2026Current reportSEC
ARS · Annual report to shareholdersApr 27, 2026Annual reportSEC
DEF 14A · Proxy statementApr 27, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 15, 2026Meeting noticeSEC
8-K · Current reportApr 10, 2026Current reportSEC
424B3 · ProspectusApr 7, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 7, 2026Other filingsSEC
S-8 · Registration statement for employee plansApr 3, 2026Offer documentSEC
POS AM · Amendment to an effective registrationApr 3, 2026Offer documentSEC
8-K · Current reportMar 26, 2026Current reportSEC
10-K · Annual reportMar 26, 2026Annual reportSEC
8-K · Current reportMar 26, 2026ResultsSEC
8-K · Current reportMar 18, 2026Current reportSEC
4 · Change in ownershipJan 27, 2026Insider tradeSEC
8-K · Current reportJan 27, 2026Management or board changeSEC
4 · Change in ownershipJan 27, 2026Insider tradeSEC
8-K · Current reportJan 16, 2026Material contractSEC
424B4 · ProspectusJan 16, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveJan 16, 2026Other filingsSEC
S-1MEF · Registration of more shares for the same offeringJan 15, 2026Offer documentSEC
CORRESP · Letter to the SECJan 14, 2026Other filingsSEC
CORRESP · Letter to the SECJan 14, 2026Other filingsSEC
S-1/A · Registration statement, amendedJan 12, 2026Offer documentSEC
CORRESP · Letter to the SECJan 7, 2026Other filingsSEC
CORRESP · Letter to the SECJan 7, 2026Other filingsSEC
CORRESP · Letter to the SECJan 5, 2026Other filingsSEC
CORRESP · Letter to the SECJan 5, 2026Other filingsSEC
FWP · Free writing prospectusJan 5, 2026Offer documentSEC
8-K · Current reportJan 5, 2026ResultsSEC
S-1 · Registration statementJan 5, 2026Offer documentSEC
8-K · Current reportJan 5, 2026Current reportSEC
8-K · Current reportDec 19, 2025Current reportSEC
8-K · Current reportDec 2, 2025Current reportSEC
8-K · Current reportNov 26, 2025Current reportSEC
8-K · Current reportNov 7, 2025Current reportSEC
424B5 · ProspectusNov 6, 2025Offer documentSEC
8-K · Current reportNov 6, 2025Current reportSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
DRS · Draft registration statementOct 17, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
4 · Change in ownershipAug 13, 2025Insider tradeSEC
8-K · Current reportAug 7, 2025Current reportSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
8-K · Current reportAug 6, 2025Current reportSEC
8-K · Current reportAug 4, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveJul 11, 2025Other filingsSEC
424B3 · ProspectusJul 10, 2025Offer documentSEC
8-K · Current reportJul 9, 2025Current reportSEC
CORRESP · Letter to the SECJul 8, 2025Other filingsSEC
UPLOAD · Letter from the SECJul 8, 2025Other filingsSEC
S-3 · Registration statementJul 2, 2025Offer documentSEC
4 · Change in ownershipJul 1, 2025Insider tradeSEC
4 · Change in ownershipJul 1, 2025Insider tradeSEC
4 · Change in ownershipJul 1, 2025Insider tradeSEC
4 · Change in ownershipJul 1, 2025Insider tradeSEC
4 · Change in ownershipJul 1, 2025Insider tradeSEC
4 · Change in ownershipJul 1, 2025Insider tradeSEC
8-K · Current reportJun 30, 2025Meeting outcomeSEC
ARS · Annual report to shareholdersJun 9, 2025Annual reportSEC
DEF 14A · Proxy statementJun 9, 2025Meeting noticeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
8-K · Current reportMay 30, 2025Current reportSEC
PRE 14A · Preliminary proxy statementMay 27, 2025Meeting noticeSEC
8-K · Current reportMay 21, 2025Current reportSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 20, 2025Big-stake noticeSEC
DMay 15, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
8-K · Current reportMay 14, 2025ResultsSEC
8-K · Current reportMay 14, 2025Material contractSEC
8-K · Current reportMay 7, 2025Current reportSEC
UPLOAD · Letter from the SECMay 6, 2025Other filingsSEC
CORRESP · Letter to the SECMay 2, 2025Other filingsSEC
UPLOAD · Letter from the SECApr 28, 2025Other filingsSEC
8-K · Current reportApr 22, 2025Current reportSEC
8-K · Current reportApr 15, 2025Current reportSEC
8-K · Current reportApr 15, 2025Current reportSEC
424B3 · ProspectusApr 4, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 4, 2025Other filingsSEC
S-8 · Registration statement for employee plansMar 27, 2025Offer documentSEC
POS AM · Amendment to an effective registrationMar 27, 2025Offer documentSEC
10-K · Annual reportMar 20, 2025Annual reportSEC
8-K · Current reportMar 20, 2025ResultsSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
8-K · Current reportJan 10, 2025Current reportSEC
8-K · Current reportDec 18, 2024Current reportSEC
4 · Change in ownershipDec 2, 2024Insider tradeSEC
8-K · Current reportNov 29, 2024Current reportSEC
8-K · Current reportNov 18, 2024Current reportSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
8-K · Current reportNov 4, 2024Current reportSEC
8-K · Current reportOct 7, 2024Current reportSEC
8-K · Current reportSep 30, 2024Current reportSEC
4 · Change in ownershipSep 20, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedSep 20, 2024Big-stake noticeSEC
8-K · Current reportSep 19, 2024Meeting outcomeSEC
DEF 14A · Proxy statementAug 21, 2024Meeting noticeSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
8-K · Current reportAug 14, 2024ResultsSEC
4 · Change in ownershipAug 13, 2024Insider tradeSEC
8-K · Current reportAug 13, 2024Current reportSEC
PRE 14A · Preliminary proxy statementAug 7, 2024Meeting noticeSEC
8-K · Current reportAug 6, 2024Current reportSEC
8-K · Current reportJul 30, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveJul 25, 2024Other filingsSEC
424B3 · ProspectusJul 24, 2024Offer documentSEC
CORRESP · Letter to the SECJul 22, 2024Other filingsSEC
UPLOAD · Letter from the SECJul 22, 2024Other filingsSEC
S-1 · Registration statementJul 18, 2024Offer documentSEC
8-K · Current reportJul 16, 2024Current reportSEC
4/A · Change in ownership, amendedJul 10, 2024Insider tradeSEC
DJul 1, 2024Other filingsSEC
8-K · Current reportJun 26, 2024Current reportSEC
4 · Change in ownershipJun 25, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedJun 25, 2024Big-stake noticeSEC
424B5 · ProspectusJun 25, 2024Offer documentSEC
8-K · Current reportJun 25, 2024Material contractSEC
8-K · Current reportJun 24, 2024Current reportSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
8-K · Current reportJun 7, 2024Management or board changeSEC
8-K · Current reportMay 22, 2024Current reportSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
8-K · Current reportMay 9, 2024ResultsSEC
ARS · Annual report to shareholdersApr 30, 2024Annual reportSEC
DEF 14A · Proxy statementApr 30, 2024Meeting noticeSEC
8-K · Current reportApr 30, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveApr 24, 2024Other filingsSEC
CORRESP · Letter to the SECApr 19, 2024Other filingsSEC
UPLOAD · Letter from the SECApr 17, 2024Other filingsSEC
8-K · Current reportApr 17, 2024Current reportSEC
8-K · Current reportApr 16, 2024Current reportSEC
S-3 · Registration statementApr 12, 2024Offer documentSEC
8-K · Current reportApr 1, 2024Current reportSEC
10-K · Annual reportMar 28, 2024Annual reportSEC
8-K · Current reportMar 28, 2024ResultsSEC
8-K · Current reportMar 13, 2024Current reportSEC
4 · Change in ownershipMar 4, 2024Insider tradeSEC
8-K · Current reportMar 4, 2024Management or board changeSEC
8-K · Current reportFeb 29, 2024Current reportSEC
8-K · Current reportFeb 14, 2024Current reportSEC
8-K · Current reportFeb 1, 2024Current reportSEC
8-K · Current reportJan 18, 2024Current reportSEC
8-K · Current reportJan 9, 2024Current reportSEC
8-K · Current reportDec 28, 2023Current reportSEC
8-K · Current reportDec 19, 2023Current reportSEC
8-K · Current reportDec 7, 2023Current reportSEC
4 · Change in ownershipDec 4, 2023Insider tradeSEC
10-Q · Quarterly reportNov 13, 2023Quarterly reportSEC
8-K · Current reportNov 13, 2023ResultsSEC
8-K · Current reportNov 6, 2023Management or board changeSEC
3 · Initial statement of ownershipNov 2, 2023Insider tradeSEC
3 · Initial statement of ownershipOct 30, 2023Insider tradeSEC
8-K · Current reportOct 30, 2023Management or board changeSEC
8-K · Current reportSep 22, 2023Current reportSEC
8-K · Current reportSep 19, 2023Management or board changeSEC
8-K · Current reportSep 15, 2023Current reportSEC
8-K · Current reportAug 24, 2023Material contractSEC

This page holds 200 of 639 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from MetaVia Inc.’s releases · as of Nov 9, 2026

Common shares
6,742,889
Fully diluted
6,742,889

Fully diluted

LineSharesAs of
Common shares6,742,889Nov 9, 2026

Warrants and options

Lot
Warrants · US$3.10 · expire about Jan 2031

Share count over time

CountShares
Nov 9, 20266,742,889
Sep 30, 20266,742,889
Mar 31, 20262,308,294

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Jane Street92,1411.4%US$145KSep 30, 2026
Vanguard57,1200.85%US$89,678Sep 30, 2026
Geode Capital33,7500.50%US$52,987Sep 30, 2026
Hrt Financial LP15,6100.23%US$24,000Sep 30, 2026
Virtu Financial LLC13,8250.21%US$22,000Sep 30, 2026
Aries Wealth Management10,0000.15%US$15,700Sep 30, 2026
Tower Research Capital LLC (TRC)2,6740.04%US$4,198Sep 30, 2026
Fidelity7500.01%US$1,178Sep 30, 2026
Comprehensive Financial Planning, Inc.129<0.01%US$203Sep 30, 2026
Robinhood Markets, Inc.30<0.01%US$47Sep 30, 2026
All 15 holders
HolderSharesOf the companyValueAs of
BlackRock7<0.01%US$11Sep 30, 2026
Caitong International Asset Management Co., Ltd5<0.01%US$8Sep 30, 2026
Brown Brothers Harriman & Co2<0.01%US$3Sep 30, 2026
Danske Bank A/S2<0.01%US$3Sep 30, 2026
UBS1<0.01%US$2Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Fidelity Extended Market Index Fund20,3500.30%US$57,794May 31, 2026
Vanguard Extended Market Index Fund2,2220.03%US$3,177Jun 30, 2026
Fidelity Nasdaq Composite Index Fund431<0.01%US$1,224May 31, 2026
Fidelity Total Market Index Fund431<0.01%US$1,224May 31, 2026

Big stakes

StakeStakeSharesDateFiling
Alyeska Investment Group, L.P.9.99%509KMar 31, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Mark A. Glickman
Other companies: BioStem Technologies, Inc. (Director · Since at least Aug 6, 2026); TherapeuticsMD, Inc. (Co-Chief Executive Officer · Oct 15, 2021 – Dec 6, 2022 · Past); Esperion Therapeutics, Inc. (Chief Commercial Officer · Dec 20, 2018 – Jan 2, 2020 · Past); Aralez Pharmaceuticals Inc (Chief Commercial Officer · Feb 5, 2016 – Mar 19, 2018 · Past); POZEN Inc (Chief Commercial Officer · Jun 22, 2015 – Jun 22, 2015 · Past); Auxilium Pharmaceuticals Inc (EVP - Sales and Marketing · Feb 3, 2012 – Jan 29, 2015 · Past)
Independent Director · Since at least May 11, 2023
Andy Sassine
Other companies: Arcturus Therapeutics Holdings Inc. (Chief Financial Officer, Director · Since at least Jan 1, 2019); icad inc (Director · Since at least Dec 7, 2015); Exicure, Inc. (Director · Mar 5, 2021 – Jun 2, 2021 · Past); Acorn Energy, Inc. (Director · Sep 20, 2013 – Sep 23, 2014 · Past); Emmaus Life Sciences, Inc. (Director · Feb 25, 2013 – Apr 5, 2016 · Past)
Director · Aug 4, 2016 – Jul 24, 2019 · Past
James P. Tursi
Other companies: Endo International PLC (Executive VP, Global R&D · Feb 24, 2022 – Jul 15, 2022 · Past); Antares Pharma Inc (EVP, Chief Medical Officer · Aug 6, 2018 – Jun 13, 2019 · Past); Aralez Pharmaceuticals Inc (Chief Medical Officer · Feb 5, 2016 – May 14, 2018 · Past); POZEN Inc (Chief Medical Officer · Oct 1, 2015 – Oct 1, 2015 · Past); Auxilium Pharmaceuticals Inc (Chief Medical Officer · Feb 14, 2012 – Jan 29, 2015 · Past)
Independent Director · Since at least Nov 1, 2023
Lee Golden
Other companies: Cadrenal Therapeutics, Inc. (Board Member · Since at least Nov 24, 2025); PTC Therapeutics, Inc. (EVP & CHIEF MEDICAL OFFICER · Since at least Jun 6, 2023)
Chief Medical Officer · Oct 5, 2016 – Jan 28, 2018 · Past
Jason Groves
Other companies: Medifast Inc (Executive VP & General Counsel, Director · Apr 6, 2010 – Feb 17, 2015 · Past)
Independent Director · Since at least Dec 30, 2019
Akash BakshiSVP and COO, Director · Dec 31, 2020 – Dec 31, 2020 · Past
Andrew KovenChairman of the Board · Since at least Jun 8, 2026
David LowenschussChief Legal Off. & Secretary · Aug 4, 2016 – Aug 10, 2016 · Past
D. Gordon StricklandDirector · Since at least Jan 27, 2022
Hyung Heon KimChief Executive Officer and President · Since at least Jul 9, 2021
All 17 people
PersonSeat
Jeong Gyun OhDirector · Dec 30, 2019 – Jan 13, 2020 · Past
Joseph HookerInterim CEO and President · Jan 12, 2023 – Jan 12, 2023 · Past
Marshall H. WoodworthChief Financial Officer · Since at least Oct 28, 2026
Michael SalsburyDirector · Since at least Jun 9, 2022
Nicola ShannonVP, Clinical Operations · Dec 30, 2019 – Dec 30, 2019 · Past
Richard KangDirector · Dec 30, 2019 – Jun 9, 2022 · Past
Sarah BrowneChief Medical Officer · Since at least Oct 12, 2026

Open People

Log in to ask 6ix AI your own questions about MetaVia Inc.